ARD: Increased immunogenicity after a third dose of homologous inactivated SARS-CoV-2 vaccine in a large number of autoimmune rheumatic patients in Brazil

OBJECTIVE : To determine the immunogenicity of a third dose of CoronaVac vaccine in a large number of patients with autoimmune rheumatic disease (ARD) and factors associated with impaired respon.

Objectives : To determine the immunogenicity of a third dose of CoronaVac vaccine in a large number of patients with autoimmune rheumatic disease (ARD) and factors associated with impaired respon.

Methods Adult patients with ARD who had previously received two doses of CoronaVac and age-balanced / sex-balanced controls (control group, CG ) received a third dose on D210 ( 6 months after the second dose.

Results ARD (n=597) and CG (n=199) were comparable in age (p=94

Conclusions This study provides new data on the strong response to a third dose of CoronaVac in patients with autoimmune rheumatic disease (ARD) , even in patients with pre-vaccination COVID-19 seronegative statu.

Source: Aikawa NE, Kupa LDVK, Medeiros-Ribeiro AC , et a.

Aikawa NE, Kupa LDVK, Medeiros-Ribeiro AC , et a.
Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseas.
Annals of the Rheumatic Diseases2022; 81: 1036-104 , et al Annals of the Rheumatic Diseases81: Comment here